1. Rao DS, Chang JC, Kumar PD, Mizukami IF, Smithson G, Bradley SV, Parlow AF, Ross TS, (2001). “Huntingtin Interacting Protein 1 is a clathrin coat binding protein required for the differentiation of late spermatogenic progenitors”. Molecular and Cellular Biology, 21(22): 7796-7806.
  2. Rao DS, Hyun TS, Kumar PD, Mizukami IF, Lucas P, Rubin M, Sanda M, Ross TS (2002). “Huntingtin-interacting protein 1 is over-expressed in prostate and colon cancer and is critical for cellular survival.” Journal of Clinical Investigation, 110: 351-360.
  3. Rao DS, Bradley SV, Kumar PD, Hyun TS, Saint-dic DS, Oravecz-Wilson KI, Kleer CG, Ross TS (2003). “Altered Receptor Trafficking in Huntingtin-Interacting Protein 1-transformed cells”. Cancer Cell, 3: 471-482.
  4. Hyun TS, Rao DS, Saint-Dic D, Evan Michael L, Kumar PD, Bradley SV, Mizukami IF, Oravecz-Wilson KI, Ross TS (2004). HIP1 and HIP1r stabilize receptor tyrosine kinases and bind 3-phosphoinositides via ENTH domains. Journal of Biological Chemistry. 279(14):14294-306.
  5. Oravecz-Wilson KI, Kiel MJ, Li L, Rao DS, Saint-Dic D, Kumar PD, Provot MM, Hankenson KD, Reddy VN, Lieberman AP, Morrison SJ, Ross TS (2004). Huntingtin Interacting Protein 1 mutations lead to abnormal hematopoiesis, spinal defects and cataracts. Human Molecular Genetics. 13(8):851-67.
  6. Rao DS, Goldin JG, Fishbein MC (2005). Determinants of plaque instability in atherosclerotic vascular disease. Cardiovascular Pathology. Nov-Dec;14(6):285-93.
  7. Rao DS, Infeld MD, Stern RC, Chelimsky TC (2006). Cough-induced hemiplegic migraine with impaired consciousness in cystic fibrosis. Pediatric Pulmonology. 41(2):171-6.
  8. Kaluza V, Rao DS, Said JW, de Vos S (2006).  Primary extranodal nasal-type natural killer/T-cell lymphoma of the brain: a case report.  Human Pathology. 37(6):769-72.
  9. Pham PH, Rao DS, Vasunilashorn F, Fishbein MC, Goldin JG (2006). Computed Tomography Calcium Quantification as a Measure of Atherosclerotic Plaque Morphology and Stability.  Invest Radiol. 41(9):674-680.
  10. Rao DS, Gui D, Koski ME, Popoviciu LM, Wang H, Reiter RE, Said JW (2006).  An Inverse Relation Between COX-2 and E-cadherin Expression Correlates With Aggressive Histologic Features in Prostate Cancer. Appl Immunohistochem Mol Morphol. 14(4):375-383.
  11. O'Connell RM, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J, Paquette RL, Baltimore D (2008).  Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Experimental Medicine, 205(3):585-94.
  12. Pullarkat ST, Vardiman JW, Slovak ML, Rao DS, Rao NP, Bedell V, Said JW (2008). Megakaryocytic blast crisis as a presenting manifestation of chronic myeloid leukemia. Leukemia Research. 32(11):1770-5.
  13. O’Connell RM*, Chaudhuri AA*, Rao DS*, Baltimore D (2009).  Inositol phosphatase SHIP1 is a primary target of miR-155. Proc Natl Acad Sci USA. 106:7113-8 (*Joint first authorship).
  14. Rao DS, O’Connell RM, Chaudhuri AA, Garcia-Flores Y, Geiger T, Baltimore D (2010). MicroRNA-34a perturbs B-cell development by targeting the Forkhead transcription factor Foxp1.  Immunity, 33(1):48-59.
  15. O'Connell RM, Chaudhuri AA, Rao DS, Gibson WS, Balazs AB, Baltimore D (2010). “MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output”.  Proc Natl Acad Sci USA, 107(32):14235-40.
  16. O'Connell RM, Balazs AB, Rao DS, Kivork C, Yang L, Baltimore D (2010). “Lentiviral Vector Delivery of Human Interleukin-7 (hIL-7) to Human Immune System (HIS) Mice Expands T Lymphocyte Populations.” PLoS ONE 5(8): e12009. doi:10.1371/journal.pone.0012009.
  17. O’Connell RM, Kahn D, Gibson WSJ, Round JL, Scholz RL, Chaudhuri AA, Kahn ME, Rao DS, Baltimore D (2010). MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development.  Immunity, 33(4):607-19.
  18. Boldin MP, Taganov KD, Rao DS, Yang L, Zhao JL, Kalwani M, Garcia-Flores Y, Luong M, Devrekanli A, Xu J, Sun G, Tay J, Linsley PS, Baltimore D (2011). “miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice.”  J Exp Med, 208(6):1189-201.
  19. Zhao JL*, Rao DS*, Boldin MP, Taganov KD, O’Connell RM, Baltimore D (2011). “NF-B dysregulation in microRNA-146a–deficient mice drives the development of myeloid malignancies.”  Proc Natl Acad Sci USA, 108(22):9184-9. (*Joint first authorship).
  20. Balasz AB, Chen J, Hong CM, Rao DS, Yang L, Baltimore D (2012). “Antibody-based protection against HIV infection by vectored immunoprophylaxis.” Nature, 481(7379):81-4.
  21. Chaudhuri AA, So AY, Mehta A, Minisandram A, Sinha N, Jonsson VD, Rao DS, O'Connell RM, Baltimore D (2012). “Oncomir miR-125b regulates hematopoiesis by targeting the gene Lin28A.” Proc Natl Acad Sci USA, 109(11):4233-8.
  22. Hur EM, Patel SN, Shimizu S, Rao DS, Gnanapragasam PN, An DS, Yang L, Baltimore D (2012). “Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice.” Blood, 120(23):4571-82.
  23. Pigazzi M, Manara E, Bresolin S, Tregnago C, Beghin A, Baron E, Giarin E, Cho EC, Masetti R, Rao DS, Sakamoto KM, Basso G (2013). “MiR-34b promoter hypermethylation induces CREB overexpression and contributes to myeloid transformation.” Hematologica, 98(4):602-10.
  24. Zhao JL, Rao DS, O’Connell RM, Garcia-Flores Y, Baltimore D (2013). “MicroRNA-146a acts as a guardian of the quality and longevity of hematopoietic stem cells in mice” eLife; May 21;2:e00537. doi: 10.7554/eLife.00537. Print 2013.
  25. Balasz AB, Bloom JD, Hong CM, Rao DS, Baltimore D (2013). “Broad Protection Against Influenza by Vectored ImmunoProphylaxis”. Nature Biotechnology, 31(7):647-5. 2doi: 10.1038/nbt.2618. [Epub ahead of print].
  26. Basak SK, Veena MS, Oh S, Lai C, Vangala S, Elashoff D, Fishbein MC, Sharma S, Rao NP, Rao D, Phan R, Srivatsan ES, Batra RK (2013). “The CD44(high) Tumorigenic Subsets in Lung Cancer Biospecimens Are Enriched for Low miR-34a Expression”. PLos One, 8(9):e73195.
  27. Tirado CA, Shabsovich D, Denicola M, Rao D, Yang L, Garcia R, Rao N (2013). “A case of pediatric B-Lymphoblastic leukemia presenting with a t(9;12)(p24;q11.2) involving JAK2 and concomitant MLL rearrangement with apparent insertion at 6q27.” Biomark Res. 25(1): 31.
  28. Balazs AB, Ouyang Y, Hong CM, Chen J, Nguyen SM, Rao DS, An DS, Baltimore D. (2014) “Vectored Immunoprophylaxis Protects Humanized Mice from Mucosal HIV Transmission”. Nature Medicine, 20(3):296-300.
  29. Fang J, Barker B, Bolanos L, Liu X, Jerez A, Makishima H, Christie S, Chen X, Rao DS, Grimes HL, Komurov K, Weirauch MT, Cancelas JA, Maciejewski JP, Starczynowski DT. (2014) “Myeloid Malignancies with Chromosome 5q Deletions Acquire a Dependency on an Intrachromosomal NF-κB Gene Network.Cell Rep. 8(5):1328-38.
  30. Hu R, Kagele DA, Huffaker TB, Runtsch MC, Alexander M, Blake E, Su W, Williams MA, Rao DS, Moeller T, Garden G, Round JL, O’Connell RM. (2014)“ miR-155 promotes T follicular helper cell accumulation during chronic, low-grade inflammation”. Immunity, 41(4): 605-619.
  31. Fernando TR, Rodriguez-Malave NI, Waters EW, Yan W, Casero D, Pigazzi M, Basso G, Rao DS (2015) “LincRNA expression discriminates cytogenetic subtypes in B-lymphoblastic leukemia and plays a functional role in leukemia cell survival”. Mol Cancer Research, 13(5):839-51 [Corresponding author]
  32. Contreras JR , Palanichamy JK , Tran T , Fernando TR ,  Rodriguez-Malave NI, Arboleda VA, Casero D, and Rao DS (2015) “MicroRNA-146a modulates B-cell oncogenesis by targeting Egr1.” Oncotarget, 6: 11023-37. [Corresponding Author]
  33. Rodríguez-Malavé NI, Fernando TR, Patel PC, Contreras JR, Palanichamy JK, Tran TM, Anguiano J, Davoren MJ, Alberti MO, Pioli KT, Sandoval S, Crooks GM, Rao DS (2015). "BALR-6 regulates cell growth and cell survival in B-lymphoblastic leukemia".  Mol Cancer.  14(1):214. [Corresponding Author] (IMPACT FACTOR: 44)
  34. Palanichamy JK, Tran TM, Howard JM, Contreras JR, Fernando TR, Sterne-Weiler T, Katzman S, Taloue M, Yan, W, Basso G, Pigazzi M, Sanford JR, Rao DS (2016). “RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation”. Journal of Clinical Investigation, 126(4):1495-511. doi: 10.1172/JCI80046. Epub 2016 Mar 14. [Corresponding Author]
  35. Wallace J, Hu R, Mosbruger TL, Dahlem TJ, Stephens WZ, Rao DS, Round JL, O’Connell RM (2016). “Genome-wide CRISPR-Cas9 screen identifies microRNAs that regulate myeloid leukemia cell growth”. PloS one. 2016; 11(4):e0153689.
  36. King JK, Ung NM, Paing MH, Contreras JR, Alberti MO, Fernando TR, Zhang K, Pellegrini M, Rao DS (2017). “Regulation of marginal zone B-cell development by microRNA-146a”. Frontiers in Immunology. 7:670. doi: 10.3389/fimmu.2016.00670. [Corresponding Author]
  37. Wallace JA, Kagele D, Eiring AM, Kim CN, Hu R, Runtsch MC, Alexander M, Huffaker TB, Lee S-H, Patel AB, Mosburger TL, Voth W, Rao DS, Miles RR, Round JL, Deininger MWN, O’Connell RM (2017). “miR-155 promotes FLT3-ITD-induced myeloproliferative disease through inhibition of the interferon response”. Blood, 129(23):3074-3086. doi: 10.1182/blood-2016-09-740209. Epub 2017 Apr 21.
  38. Fernando TR, Contreras JR, Zampini M, Rodriguez-Malave NI, Alberti MO, Anguiano J, Tran TM, Palanichamy JK, Gajeton J, Ung NM, Aros CJ, Waters EV, Casero D, Basso G, Pigazzi M, Rao DS (2017). “The lncRNA CASC15 regulates SOX4 expression in RUNX1-rearranged acute leukemia”. Mol Cancer, 16(1): 126.  doi: 10.1186/s12943-017-0692-x [Corresponding author].
  39. Li B, Wang X, Choi IY, Wang YC, Liu S, Pham AT, Moon H, Smith DJ, Rao DS, Boldin MP, Yang L. (2017) “miR-146a modulates autoreactive Th17 cell differentiation and regulates organ-specific autoimmunity”. Journal of Clinical Investigation. 127(10):3702-3716. doi: 10.1172/JCI94012. Epub 2017 Sep 5.
  40. Sasine JP, Himburg HA, Termini CM, Roos M, Tran E, Zhao L, Kan J, Li M, Zhang Y, de Barros SC, Rao DS, Counter CM, Chute JP (2018). Wild-type Kras expands and exhausts hematopoietic stem cells. JCI Insight. 3(11):e98197.  
  41. Ekiz HA, Ramstead AG, Lee S-H, Nelson M, Bauer KM, Hu R, Round JL, Rutter J, Rao DS, O’Connell RM (2020). “T cell-expressed miR-155 reduces lifespan in a mouse model of chronic, low-grade inflammation”. Journal of Immunology. 204(8):2064-2075.
  42. Jaiswal AK, Truong H, Tran TM, Lin TL, Casero D, Alberti MO, Rao DS (2021). Focused CRISPR-Cas9 genetic screening reveals USO1 as a vulnerability in B-cell acute lymphoblastic leukemia. Scientific Reports. 11(1):13158 [Corresponding author].
  43. Tran TM, Philipp J, Bassi J, Nibber N, Draper J, Lin TL, Palnichamy JK, Jaiswal AK, Silva O, Paing M, King JK, Katzman S, Sanford JR, Rao DS (2021). “The RNA binding protein IGF2BP3 is critical for MLL-AF4 mediated leukemogenesis”.  Leukemia. 2022 Jan;36(1):68-79. doi: 10.1038/s41375-021-01346-7. Epub 2021 Jul 29. PMCID: PMC8727287. [Corresponding author].
  44. Porcu E, Benetton M, Bisio V, Da Ros A, Tregnano C, Borella G, Zanon C, Bordi M, Germano G, Manni S, Campello S, Rao DS, Locatelli F, Pigazzi M. (2021).  “The long non coding RNA CDK6-AS1 overexpression impacts on acute myeloid leukemia differentiation and mitochondrial dynamics”. iScience, 24(11):103350. doi: 10.1016/j.isci.2021.103350. eCollection 2021 Nov 19.
  45. Jumniensuk C, Nobori A, Lee T, Senaratne TN, Rao D, Pullarkat S. (2022) “Concordance of Peripheral Blood and Bone Marrow Next-Generation Sequencing in Hematologic Neoplasms”. Advances in Hematology. 2022 Mar 26;2022:8091746. doi: 10.1155/2022/8091746. eCollection 2022.
  46. King JK, Tran TM, Paing MH, Yin Y, Jaiswal AK, Tso CH,  Roy K, Casero D, Rao DS (2022) “Regulation of T-Independent B-Cell Responses by MicroRNA-146a”, Frontiers in Immunology. 13:984302. doi: 10.3389/fimmu.2022.984302 [Corresponding Author]
  47. Palanichamy JK, Tran TM, King JK, Katzman S, Ritter AJ, Sharma G, Tso C, Contreras JR, Fernando TR, Sanford JR, Rao DS (2023). “Distinct Oncogenic Phenotypes in hematopoietic specific deletions of Trp53”. Scientific Reports, 13(1):7490. [Corresponding Author]
  48. Ghazaryan A, Wallace JA, Tang WW, Barba C, Lee S-H, Bauer K, Nelson MC, Kim CN, Stubben C, Voth WP, Rao DS, O’Connell RM (2023). “miRNA-1 promotes Acute Myeloid Leukemia cell pathogenesis through metabolic regulation”. Frontiers in Genetics, 2023 May 9;14:1192799. doi: 10.3389/fgene.2023.1192799.


  1. Rao DS and Said JW  (2007) “Small lymphoid proliferations in extranodal locations”.  Archives of Pathology and Laboratory Medicine. 131(3):383–396 .
  2. Baltimore D, Boldin MP, O'Connell RM, Rao DS, Taganov KD (2008). “MicroRNAs: new regulators of immune cell development and function.” Nature Immunology. 9(8):839-45.
  3. O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. (2010) “Physiological and pathological roles for microRNAs in the immune system”. Nature Reviews Immunology. 10(2):111-22.
  4. O’Connell RM, Jhao JL, Rao DS (2011) “MicroRNA function in myeloid Biology”. Blood, 118(11):2960-9. [Corresponding author]
  5. Contreras J and Rao DS (2012) “MicroRNAs in inflammation and immune responses”.  Leukemia, 26(3):404-13. Epublished Dec 20, 2011.  [Corresponding author]
  6. O’Connell RM, Rao DS, Baltimore D (2012) “microRNA regulation of inflammatory responses”.  Annual Reviews of Immunology, 30:295-312.
  7. Fernando TR, Rodriguez-Malave NI, Rao DS (2012) “microRNAs in B-cell development and malignancy.” Journal of Hematology and Oncology, Mar 8, 5:7.  [Corresponding author]
  8. Palanichamy JK, Rao DS (2014) “miRNA dysregulation in cancer: towards a mechanistic understanding”. Frontiers in Genetics. Mar 18; 5:54. [Corresponding Author]
  9. Rodriguez-Malave NI, Rao DS (2016) “Long non-coding RNA in hematologic malignancies". Brief Funct Genomics. 15 (3):227-38. [Epub Nov 26, 2015] [Corresponding Author]
  10. Rao DS and O’Connell, RM (2020). “Micro-sized inflammaging protects stem cells”, Blood. 2020 Jun 18;135(25):2204-2205.
  11. Pollyea DA, Bixby D, Perl A, Bhatt VR, Altman JK, Appelbaum FR, de Lima M, Fathi AT, Foran JM, Gojo I, Hall AC, Jacoby M, Lancet J, Mannis G, Marcucci G, Martin MG, Mims A, Neff J, Nejati R, Olin R, Percival ME, Prebet T, Przespolewski A, Rao D, Ravandi-Kashani F, Shami PJ, Stone RM, Strickland SA, Sweet K, Vachhani P, Wieduwilt M, Gregory KM, Ogba N, Tallman MS (2021). “NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021”. J Natl Compr Canc Netw. 2021 Jan 6;19(1):16-27. doi: 10.6004/jnccn.2021.0002.
  12. Tran TM and Rao DS (2022). “RNA Binding Proteins in MLL-rearranged leukemia”. Experimental Hematology and Oncology 11:80. [Corresponding Author]
  13. Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, Gojo I, Hall AC, Jonas BA, Kishtagari A, Lancet J, Maness L, Mangan J, Mannis G, Marcucci G, Mims A, Moriarty K, Mustafa Ali M, Neff J, Nejati R, Olin R, Percival ME, Perl A, Przespolewski A, Rao D, Ravandi F, Shallis R, Shami PJ, Stein E, Stone RM, Sweet K, Thota S, Uy G, Vachhani P, Cassara CJ, Freedman-Cass DA, Stehman K. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 May;21(5):503-513. doi: 10.6004/jnccn.2023.0025.